Sylvie Labrecque
Impact in
- Oncology top 5%
- Cancer-related Molecular Pathways
- Cancer Research top 10%
Papers in
- Oncology 7
- Cancer-related Molecular Pathways 6
-
- Cancer Research and Treatments 3
- Co-authors
- Greg Matlashewski (8 shared papers)Lawrence Banks (2 shared papers)Ann Kalita (1 shared paper)Miranda Thomas (1 shared paper)David Pim (1 shared paper)David M. Thomson (1 shared paper)Antonis E. Koromilas (1 shared paper)Suiyang Li (1 shared paper)
In The Last Decade
Sylvie Labrecque
10 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 69
- Oncology 662
- Cancer Research 187
- Epidemiology 357
- Biotechnology 98
- Immunology 228
Countries citing papers authored by Sylvie Labrecque
This map shows the geographic impact of Sylvie Labrecque's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sylvie Labrecque with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sylvie Labrecque more than expected).
Fields of papers citing papers by Sylvie Labrecque
This network shows the impact of papers produced by Sylvie Labrecque. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sylvie Labrecque. The network helps show where Sylvie Labrecque may publish in the future.
Co-authors
The 22 scholars most cited alongside Sylvie Labrecque, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 1999 | 612 | |
| 2 | 1999 | 238 | |
| 3 | Analysis of the anti-p53 antibody response in cancer patients. | 1993 | 127 |
| 4 | 2000 | 82 | |
| 5 | 1993 | 56 | |
| 6 | 2001 | 54 | |
| 7 | DNA damage induced p53 mediated transcription is inhibited by human papillomavirus type 18 E6. | 1994 | 41 |
| 8 | Viability of wild type p53-containing and p53-deficient tumor cells following anticancer treatment: the use of human papillomavirus E6 to target p53. | 1995 | 25 |
| 9 | 2000 | 12 | |
| 10 | 2000 | 8 |
About Sylvie Labrecque
Sylvie Labrecque is a scholar working on Oncology, Biotechnology, Epidemiology, Immunology and Public Health, Environmental and Occupational Health, having authored 10 papers that have together received 1.3k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (6 papers), Cervical Cancer and HPV Research (4 papers), Cancer Research and Treatments (3 papers), Molecular Biology Techniques and Applications (3 papers), Research on Leishmaniasis Studies (2 papers), T-cell and Retrovirus Studies (1 paper), interferon and immune responses (1 paper) and Cancer, Hypoxia, and Metabolism (1 paper). The work is most often cited by research in Oncology (662 citations), Cancer Research (187 citations), Epidemiology (357 citations), Biotechnology (98 citations) and Immunology (228 citations). Sylvie Labrecque has collaborated with scholars based in Canada, Czechia and Italy. Frequent co-authors include Greg Matlashewski, Lawrence Banks, Ann Kalita, Miranda Thomas, David Pim, David M. Thomson, Antonis E. Koromilas, Suiyang Li, Sandra Pellegrini and Maria Cristina Gauzzi. Their work appears in journals such as International Journal of Cancer, Vaccine, Journal of Biotechnology, Molecular and Cellular Biology and The Journal of Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.